Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients

Pharmacogenomics

Volumn 12, Issue 7, 2011, Pages 977-984

  Miura, Masatomo ^a   Satoh, Shigeru ^a   Kagaya, Hideaki ^a   Saito, Mitsuru ^a   Numakura, Kazuyuki ^a   Tsuchiya, Norihiko ^a   Habuchi, Tomonori ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CYP3A4; CYP3A5; pharmacogenomics; polymorphism n tacrolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE AMINOTRANSFERASE; BASILIXIMAB; BILIRUBIN; COTRIMOXAZOLE; CREATININE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RABEPRAZOLE; SERUM ALBUMIN; TACROLIMUS; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; PHARMACOLOGICAL BIOMARKER;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CONTINUOUS INFUSION; CREATININE CLEARANCE; CYP3A4 GENE; CYP3A5 GENE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG HALF LIFE; EVENING DOSAGE; FEMALE; GENDER; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; DOSE RESPONSE; GENETICS; MIDDLE AGED;

ADULT; AGED; BIOMARKERS, PHARMACOLOGICAL; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 79960810087     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.33     Document Type: Article

References (28)

1. Venkataramanan R, Swaminathan A, Prasad T et al.: Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 29(6), 404-430 (1995). (Pubitemid 26004179)
2. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin. Pharmacokinet. 43(10), 623-653 (2004). (Pubitemid 38981845)
3. Haufroid V, Wallemacq P, van Kerckhove V et al.: CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am. J. Transplant. 6(11), 2706-2713 (2006). (Pubitemid 44571691)
4. Hesselink DA, van Schaik RH, van der Heiden IP et al.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 74(3), 245-254 (2003). (Pubitemid 37083100)
5. Tsuchiya N, Satoh S, Tada H et al.: Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation 78(8), 1182-1187 (2004). (Pubitemid 39426437)
6. Roy JN, Barama A, Poirier C, Vinet B, Roger M: CYP3A4, CYP3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet. Genomics 16(9), 659-665 (2006). (Pubitemid 44223077)
7. Tada H, Tsuchiya N, Satoh S et al.: Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant. Proc. 37(4), 1730-1732 (2005). (Pubitemid 40790812)
8. Haufroid V, Mourad M, van Kerckhove V, et al.: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14(3), 147-154 (2004). (Pubitemid 38373108)
9. Satoh S, Kagaya H, Saito S et al.: Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br. J. Clin. Pharmacol. 66(2), 207-214 (2008).
10. Lin YS, Dowling AL, Quigley SD et al.: Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 62(1), 162-172 (2002). (Pubitemid 34680528)
11. Lamba JK, Lin YS, Schuetz EG, Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug. Deliv. Rev. 54(10), 1271-1294 (2002). (Pubitemid 35284253)
12. Satoh S, Saito M, Inoue T et al.: CYP3A5*1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 65(5), 473-481 (2009).
13. Fukushima-Uesaka H, Saito Y, Watanabe H et al.: Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum. Mutat. 23(1), 100-108 (2004).
14. Gao Y, Zhang LR, Fu Q: CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur. J. Clin. Pharmacol. 64(9), 877-882 (2008).
15. Du J, Zhang A, Wang L et al.: Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J. Psychopharmacol. 24(7), 1115-1120 (2010).
16. Zhang W, Chang YZ, Kan QC et al.: CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur. J. Clin. Pharmacol. 66(1), 61-66 (2010).
17. Fukuen S, Fukuda T, Maune H et al.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 12(4), 331-334 (2002). (Pubitemid 34620661)
18. Obayashi K, Nakamura K, Kawana J et al.: VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80(2), 169-178 (2006). (Pubitemid 44160690)
19. Shiran MR, Lennard MS, Iqbal MZ et al.: Contribution of the activities of CYP3A4, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br. J. Clin. Pharmacol. 67(1), 29-37 (2009).
20. Kitamura Y, Moriguchi M, Kaneko H et al.: Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann. Hum. Genet. 66(Pt 3), 183-193 (2002).
21. MacPhee IA, Fredericks S, Tai T et al.: The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4(6), 914-919 (2004). (Pubitemid 38745590)
22. Spurr NK, Gough AC, Stevenson K, Wolf CR: The human cytochrome P450 CYP3A locus: assignment to chromosome 7q22-qter. Hum. Genet. 81(2), 171-174 (1989). (Pubitemid 19039864)
23. Finta C, Zaphiropoulos PG: The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 260(1-2), 13-23 (2000).
24. Domanski TL, Halpert JR: Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr. Drug Metab. 2(2), 117-137 (2001). (Pubitemid 32536998)
25. Kuehl P, Zhang J, Lin Y et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001). (Pubitemid 32268418)
26. Stevens JC: New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov. Today 11(9-10), 440-445 (2006).
27. Kuypers DR, de Jonge H, Naessens M, Lerut E, Verbeke K, Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007). (Pubitemid 350114816)
28. Miura Y, Satoh S, Saito M, et al.: Factors increasing quantitative interstitial fibrosis from 0-hour to 1-year in living kidney transplant patients receiving tacrolimus. Transplantation 91(1), 78-85 (2011).